Clinical Research Directory

Safety and Clinical Activity of QEL-001 in A2-mismatch Liver Transplant Patients

The purpose of this study is to evaluate the safety and tolerability of QEL-001 in the prevention of liver transplant rejection following immunosuppression withdrawal. QEL-001 is a product made from a patients own cells, which are genetically modified and designed to help the transplant recipient's body accept their donated liver and prevent their immune system from rejecting it once immune suppression is withdrawn.

Prospective Study of White Blood Cells

The purpose of this study is to investigate white blood cells from volunteering donors to support the development of engineered regulatory T cell therapies.

Transcriptomics as an Aid in the Histological Diagnosis of Acute Rejection After Liver Transplantation

The primary objective of this exploratory study is to identify genes associated with acute rejection in liver transplant patients. To this end, a panel of acute rejection indicator genes (both humoral and cell-mediated) will be selected from results published in the literature and applied to biological material derived from biopsies. The secodnary objective is to identify genes associated with the diagnosis of humoral acute rejection and those associated with the diagnosis of cell-mediated acute rejection.

Tissue Analysis of Liver Grafts as a Predictor of Transplant Outcome.

Despite the good clinical results in terms of outcome with the application of HOPE prior to liver transplantation, very little is still known about the phenotypic and molecular changes that occur during perfusion/preservation during HOPE, particularly with regard to endothelial trophism and activation. Delving into these aspects would be very useful to allow personalised perfusion treatments in the future, thus improving the outcome of transplantation.